Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis Clear all
Completed Phase 2 Interventional

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

NCT05798520
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
BIIB091, DRF, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
23
States / cities
Scottsdale, Arizona • Berkeley, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

NCT02738775
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Pasadena, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Natalizumab High Titer Immunogenicity and Safety

NCT00516893
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BG00002-E (natalizumab high titer)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Maitland, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

NCT00536120
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Fullerton, California • Centennial, Colorado • Farmington Hills, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 19, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

NCT00484536
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
CDP323, placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced Sep 19, 2026, 9:50 AM EDT
Completed No phase listed Observational

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

NCT04676555
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Ocrelizumab, Ofatumumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

NCT04410978
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Rebif New Formulation (RNF) Quality of Life (QOL) Study

NCT00472797
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Rebif New Formulation Non Titrated, Rebif New Formulation Titrated
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

NCT02410278
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate, montelukast, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
50
States / cities
Jonesboro, Arkansas • Carmichael, California • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

NCT01201356
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
34
States / cities
Cullman, Alabama • Oceanside, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 19, 2026, 9:50 AM EDT
Completed No phase listed Observational

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

NCT01158183
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BAY86-5046_Interferon-beta-1b
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
27
States / cities
Many Locations, Alabama • Many Locations, California • Many Locations, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 1 Interventional

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

NCT02601885
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ABT-555, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Orlando, Florida • Lenexa, Kansas • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

NCT00176592
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Betaseron, Copaxone
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 19, 2026, 9:50 AM EDT
Completed No phase listed Observational

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

NCT00464074
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • Atlanta, Georgia + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 19, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

NCT00595920
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Interventions
Tovaxin
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Sep 19, 2026, 9:50 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
99
States / cities
Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 19, 2026, 9:50 AM EDT
Withdrawn Phase 2 Interventional

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

NCT06104683
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Multiple Sclerosis
Interventions
Placebo, Pirtobrutinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Tampa, Florida • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 19, 2026, 9:50 AM EDT
Completed No phase listed Observational

Plegridy Observational Program

NCT02230969
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
peginterferon beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
50
States / cities
Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

NCT04121221
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
GA Depot, Placebo
Drug · Other
Lead sponsor
Mapi Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 19, 2026, 9:50 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201
View directory record Official record
Conditions
Multiple Sclerosis, Myasthenia Gravis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 19, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

NCT01873417
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
BG00012 (DMF)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
37
States / cities
Cullman, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 19, 2026, 9:50 AM EDT
Completed No phase listed Observational

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

NCT01070836
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
35,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
473
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucaloosa, Alabama + 386 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Sep 19, 2026, 9:50 AM EDT
Completed No phase listed Observational

Tecfidera Lymphocyte Chart Review

NCT02519413
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Homewood, Alabama • Newport Beach, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 19, 2026, 9:50 AM EDT
Completed No phase listed Observational

Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program

NCT01281657
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
fingolimod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
42
States / cities
Cullman, Alabama • Berkeley, California • Pasadena, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Sep 19, 2026, 9:50 AM EDT